The conditions to Medivir's directed share issue now satisfied

The conditions to Medivir's directed share issue now satisfied

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN
OR INTO THE UNITED STATES, AUSTRALIA, CANADA, SINGAPORE, SOUTH AFRICA,
SWITZERLAND, JAPAN OR HONG KONG OR IN ANY JURISDICTION IN WHICH THE
RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS PRESS
RELEASE DOES NOT CONSTITUTE AN OFFER OF ANY SECURITIES OF MEDIVIR.

On 3 December 2010, Medivir announced that the board of directors of
Medivir had resolved on a directed issue of 2,250,000 new class B shares
at a price of SEK 125 per share. The conditions to the issue resolution
have now been satisfied. Settlement in relation to investors will take
place on 8 December 2010 and the newly issued shares will at that time
be admitted to trading on NASDAQ OMX Stockholm.

The above information has been made public in accordance with the
Securities Market Act. The information was submitted for publication at
16.45 pm (CET) on 6 December 2010.

About Medivir
Medivir is an emerging research-based specialty pharmaceutical company
focused on the development of high-value treatments for infectious
diseases. Medivir has world class expertise in polymerase and protease
drug targets and drug development. Medivir has a strong R&D portfolio
and has recently launched its first product Xerese™/Xerclear®. Medivir's
key pipeline asset, TMC435, a protease inhibitor, is in phase 2b
clinical development for Hepatitis C and is partnered with Tibotec
Pharmaceuticals.

Xerese™/Xerclear® is an innovative treatment for cold sores, which has
been approved in both the US and Europe. It is partnered with GSK to be
sold OTC in Europe and Russia and with Meda in North America. Medivir
has retained the Rx rights for Xerclear® in Sweden and Finland.

For additional information about Medivir, please contact:    
Rein Piir, CFO & VP Investor Relations, mobile: +46 708 537 292.
For more information about the company, please visit
www.medivir.se (http://www.medivir.se/)

 IMPORTANT INFORMATION
The release, publication or distribution of this press release in
certain jurisdictions may be restricted. This press release does not
constitute an offer of, or an invitation to purchase or subscribe for,
any securities of Medivir in any jurisdiction.

This press release does not constitute or form part of an offer or
solicitation to purchase or subscribe for securities in the United
States. The securities referred to herein may not be sold in the United
States absent registration or an exemption from registration under the
US Securities Act of 1933, as amended. Medivir does not intend to
register any portion of the offering of the securities in the United
States or to conduct a public offering of the securities in the United
States. Copies of this announcement should not be made in and may not be
distributed or sent into the United States, Canada, Australia,
Singapore, South Africa, Switzerland, Japan or Hong Kong.

This announcement is not a prospectus for the purposes of Directive
2003/71/EC (such Directive, together with any applicable implementing
measures in the relevant home Member State under such Directive, the
“Prospectus Directive”). Medivir has not authorized any offer to the
public of shares or rights in any Member State of the European Economic
Area and no prospectus or other offering document has been or will be
prepared in connection with the Private Placement. With respect to each
Member State of the European Economic Area and which has implemented the
Prospectus Directive (each, a “Relevant Member State”), no action has
been undertaken to date to make an offer to the public of shares or
rights requiring a publication of a prospectus in any Relevant Member
State. In any Relevant Member State this communication is only addressed
to and is only directed at qualified investors in that Member State
within the meaning of the Prospectus Directive.

This announcement is only being distributed to and is only directed at
(i) persons who are outside the United Kingdom or (ii) to investment
professionals falling within Article 19(5) of the Financial Services and
Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”) or (iii)
high net worth companies, and other persons to whom it may lawfully be
communicated, falling within Article 49(2)(a) to (d) of the Order (all
such persons in (i), (ii) and (iii) above together being referred to as
“relevant persons”).  The securities are only available to, and any
invitation, offer or agreement to subscribe, purchase or otherwise
acquire such securities will be engaged in only with, relevant persons.
 Any person who is not a relevant person should not act or rely on this
document or any of its contents.

Carnegie Investment Bank AB and Jefferies International Limited (the
“Placing Agents”) are acting exclusively for Medivir and no one else in
connection with the private placement (the “Private Placement”) of
shares in Medivir. They will not regard any other person (whether or not
a recipient of this release) as their respective clients in relation to
the Private Placement and will not be responsible to anyone other than
Medivir for providing the protections afforded to their respective
clients nor for giving advice in relation to the Private Placement or
any transaction or arrangement referred to herein. No representation or
warranty, express or implied, is made by each of the Placing Agents as
to the accuracy, completeness or verification of the information set
forth in this release, and nothing contained in this release is, or
shall be relied upon as, a promise or representation in this respect,
whether as to the past or the future. Each of the Placing Agents assume
no responsibility for its accuracy, completeness or verification and,
accordingly, disclaim, to the fullest extent permitted by applicable
law, any and all liability which they might otherwise be found to have
in respect of this release or any such statement.

The Private Placement will be subject to the condition that any offering
of the New Shares completes and that the New Shares are issued and duly
and timely registered with the Swedish Companies Registration Office. In
particular, it should be noted that any such offering and placing
agreement relating thereto will be subject to conditions and termination
events, including those which are customary for such offerings. The
Placing Agents reserve the right to exercise or refrain from exercising
their rights in relation to the fulfillment or otherwise of any such
conditions or the occurrence of any termination event in such manner as
they may determine in their absolute discretion. Any investors in the
Private Placement will be deemed to acknowledge that any offering of the
New Shares hence may not be completed and that neither the Company nor
the Placing Agents in such event shall have any liability to the
investors. Any investors will further be deemed to acknowledge (i) the
information in this press release, (ii) that the investors are not
relying (for purposes of making any investment decision or otherwise)
upon any advice, counsel or representations (whether written or oral) of
the Company, the Placing Agents or any of their respective affiliates or
any non-public information, and (iii) that they have consulted with
their own legal, regulatory, tax, business, investment, financial, and
accounting advisers to the extent they have deemed necessary, and they
have made their own investment decisions based upon their own judgment
and upon any advice from such advisers as they have deemed necessary.
Any investors are also expected to execute a customary investor letter.
The Company has not given, and the investors have not received from the
Company, any non-public information in connection with the Private
Placement.

This press release contains "forward-looking statements”, which are
statements related to future events. In this context, forward-looking
statements often address Medivir's expected future business and
financial performance, and often contain words such as "expect,
"anticipate, "intend, "plan, "believe”, "seek, or "will”.
Forward-looking statements by their nature address matters that are, to
different degrees, uncertain and can be influenced by many factors,
including the behaviour of financial markets, fluctuations in interest
and exchange rates, commodity and equity prices and the value of
financial assets; the impact of regulation and regulatory, investigative
and legal actions; strategic actions; and numerous other matters of
national, regional and global scale, including those of a political,
economic, business and competitive nature. These factors may cause
Medivir's actual future results to be materially different than those
expressed in its forward-looking statements. Medivir does not undertake
to update its forward-looking statements.